Abstract Study Objective This study investigated race and sex differences in tacrolimus
pharmacokinetics and pharmacodynamics in stable kidney transplant recipients. Design and …

Tacrolimus exhibits inter‐patient pharmacokinetic variability attributed to CYP3A5
isoenzymes and the efflux transporter, P‐glycoprotein. Most black renal transplant recipients …

Purpose The pharmacokinetics of orally administered immediate-release, twice-daily (BID)
and modified-release, once-daily (QD) formulations of tacrolimus have high interindividual …

Background We prospectively studied renal transplant recipients receiving tacrolimus to
determine the relationship between the CYP3A4, CYP3A5, and ABCB1 genetic …

What is known and objectives Tacrolimus is characterized by a narrow therapeutic index
and a considerable inter‐and intraindividual pharmacokinetic variability. The aim of our …

Objective Tacrolimus is used clinically for the long-term treatment of antirejection of
transplanted organs in liver and kidney transplant recipients, although dose optimization is …

Objectives: The aims of this study were to develop a population pharmacokinetic model of
tacrolimus in adult kidney transplant recipients, to use this model to compare cytochrome …

We retrospectively examined the association of polymorphisms in the CYP3A, CYP2J2,
CYP2C8, and ABCB1 genes with pharmacokinetic (PKs) and pharmacodynamic (PDs) …

Background and Objective The association between the CYP3A4* 1B single nucleotide
polymorphism (SNP) and tacrolimus pharmacokinetics in different studies is controversial …

The aim of this study was to develop a population pharmacokinetic model of tacrolimus in
pediatric kidney transplant patients, identify factors that explain variability, and determine …